Peptides

BPC-157 (Oral Stable Form)

Evidence: animal_plus_anecdotal

Mechanism of Action

Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.

Dosing Protocol

Standard: Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.

Maintenance: Research indicates 250 mcg twice daily for maintenance.

Administration: oral

Timing: On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.

Duration: 4-12 weeks. Oral form enables easier long-term use compared to injectable.

Notes

Oral BPC-157 is the most accessible form for clients averse to injections. It is particularly suited for GI-targeted applications (leaky gut, IBD, gastric ulcers, NSAID gastropathy) where oral delivery places the peptide directly at the site of action. The arginate salt is the preferred oral form — standard acetate has significantly lower oral bioavailability. Some practitioners combine oral BPC-157 for systemic/GI support with injectable BPC-157 at the injury site for a dual-route approach. The FDA has moved to restrict compounded BPC-157 in 2024-2025; check current regulatory status.

Stacking

  • TB-500
  • GHK-Cu

Interactions

  • BPC-157 (injectable) [LOW] — Can use oral for systemic/GI effects and injectable for localized tissue repair simultaneously.
  • Proton pump inhibitors [LOW] — PPIs alter gastric pH; may affect oral BPC-157 stability and absorption.
  • NSAIDs [LOW] — BPC-157 may counteract NSAID gastropathy; potentially protective.

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Children under 18

Side Effects

  • Mild nausea
  • GI discomfort
  • Headache (rare)

Key Papers

  • 10.1016/j.lfs.2018.07.004
  • 10.3390/pharmaceutics18020185

Source Quality

Compounding pharmacy (503A/503B) for capsules. Verify arginate salt form on COA. Third-party tested oral supplements also available (ProHealth, Integrative Peptides).

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should BPC-157 (Oral Stable Form) Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds